Attached files

file filename
EX-10.72 - EXHIBIT 10.72 - IsoRay, Inc.v332141_ex10-72.htm

 

 

United States Securities And Exchange Commission
Washington, DC 20549

 

FORM 8-K

 

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

 

Date of Report (Date of Earliest Event Reported): January 15, 2013

(January 9, 2013)

 

ISORAY, INC.

(Exact name of registrant as specified in its charter)

 

Minnesota
(State or other jurisdiction
of incorporation)
001-33407
(Commission
File Number)
41-1458152
(IRS Employer
Identification No.)

 

350 Hills Street, Suite 106, Richland, Washington 99354

(Address of principal executive offices) (Zip Code)

 

(509) 375-1202

(Registrant's telephone number)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
¨  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 
 

 

ITEM 1.01 Entry into a Material Definitive Agreement

 

On January 9, 2013, IsoRay Medical, Inc. ("Medical"), a wholly owned subsidiary of IsoRay, Inc. (the "Registrant"), entered into a supply contract (the "Agreement") with The Open Joint Stock Company ‹‹Isotope››, a Russian company ("JSC Isotope"). With the Agreement, Medical will purchase Cesium-131 from JSC Isotope and JSC Isotope will provide Cesium-131 from the Institute of Nuclear Materials within the quality standards and within the time periods specified, through June 30, 2014.

 

ITEM 9.01 Exhibits

 

(c)Exhibits
     
  10.72 Contract, dated January 9, 2013, by and between IsoRay Medical, Inc. and The Open Joint Stock Company ‹‹Isotope›› (confidential treatment requested for redacted portions)

 

SIGNATURES

 

In accordance with the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

 

Dated:  January 15, 2013    
     
     
  IsoRay, Inc., a Minnesota corporation
     
     
  By:    /s/ Dwight Babcock
    Dwight Babcock, CEO